Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

INSPIRE Pipeline™ Shield Post Approval Study

NCT: NCT05071963 · ACTIVE_NOT_RECRUITING

NCT IDNCT05071963
StatusACTIVE_NOT_RECRUITING
Start Date2021-12-20
Completion2028-04
SponsorMedtronic Neurovascular Clinical Affairs (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.

Frequently Asked Questions

What is INSPIRE Pipeline™ Shield Post Approval Study?

INSPIRE Pipeline™ Shield Post Approval Study is a clinical trial registered under NCT05071963. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05071963?

The current status of NCT05071963 (INSPIRE Pipeline™ Shield Post Approval Study) is: ACTIVE_NOT_RECRUITING.

When did INSPIRE Pipeline™ Shield Post Approval Study start?

INSPIRE Pipeline™ Shield Post Approval Study started on 2021-12-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.